Virax Biolabs Group Limited (VRAX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Virax Biolabs Group Limited (VRAX) trades at $3.45 with AI Score 44/100 (Grade C). Virax Biolabs Group Limited focuses on diagnostics and prevention solutions for viral diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VRAX: VRAX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRAX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VRAX: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Virax Biolabs Group Limited (VRAX) Healthcare & Pipeline Overview
Virax Biolabs Group Limited provides diagnostic and preventative solutions in the immunology field, offering rapid tests, PPE, and med-tech products under the ViraxClear and ViraxCare brands. The company serves a diverse global clientele, including clinics, hospitals, corporations, and individual consumers, operating in a competitive biotechnology landscape.
What Is the Investment Thesis for VRAX?
Virax Biolabs Group Limited operates in the growing market for infectious disease diagnostics and prevention. Key value drivers include expansion of its ViraxClear and ViraxCare product lines into new geographic markets and increased adoption of its online platform. The company's negative profit margin of -189001.7% and gross margin of -8774.5% highlight the need for improved operational efficiency and cost management. A beta of 1.71 suggests higher volatility compared to the market. Growth catalysts include potential partnerships with healthcare providers and increased demand for diagnostic testing. However, the company faces risks related to competition, regulatory hurdles, and the need for continuous innovation to stay ahead of emerging viral threats.
Based on FMP financials and quantitative analysis
VRAX Key Highlights
Virax Biolabs Group Limited operates in the biotechnology industry, focusing on diagnostics and preventative solutions for viral diseases.
- The company offers a range of diagnostic test kits under the ViraxClear brand, including rapid antibody, antigen, and PCR tests.
- Virax Biolabs distributes med-tech and PPE products under the ViraxCare brand, catering to healthcare providers, corporations, and individual consumers.
- The company operates internationally, with a presence in Europe, South America, Asia Pacific, and Sub-Saharan Africa.
- The company reported a negative profit margin of -189001.7% and a negative gross margin of -8774.5%.
Who Are VRAX's Competitors?
VRAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| GTBP GT Biopharma, Inc. | $0.28 | -1.71% | $8.90M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRAX's Key Strengths?
Diverse product portfolio in diagnostics and preventative healthcare.
- Established brand recognition through ViraxClear and ViraxCare.
- International presence in multiple geographic markets.
- Online platform for direct-to-consumer sales.
What Are VRAX's Weaknesses?
Negative profit margin and gross margin.
- Limited financial resources for research and development.
- High beta indicating increased volatility.
- Relatively small employee base of 17.
What Could Drive VRAX Stock Higher?
Potential partnerships with healthcare providers to expand distribution network.
- Development and launch of new diagnostic tests and preventative healthcare solutions.
- Expansion of online platform and direct-to-consumer sales initiatives.
- Efforts to improve operational efficiency and reduce costs.
What Are the Key Risks for VRAX?
Financial-distress signal — its Altman Z-Score of -9.58 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established biotechnology companies.
- Regulatory hurdles and compliance requirements in international markets.
- Negative profit margin and gross margin impacting financial stability.
- Dependence on specific products and markets, increasing vulnerability to market shifts.
What Are the Growth Opportunities for VRAX?
- Expansion into New Geographic Markets: Virax Biolabs has the opportunity to expand its presence in underserved markets across Asia Pacific and Africa. These regions are experiencing increased healthcare spending and a growing demand for diagnostic testing and preventative healthcare solutions. By establishing strategic partnerships with local distributors and healthcare providers, Virax Biolabs can increase its market share and revenue streams. The market size for diagnostics in these regions is projected to reach $15 billion by 2028, offering a substantial growth opportunity.
- Development of Advanced Diagnostic Technologies: Investing in research and development to create more advanced and accurate diagnostic tests can provide Virax Biolabs with a competitive edge. The company can focus on developing next-generation PCR tests and point-of-care diagnostics that offer faster results and improved sensitivity. The global market for advanced diagnostics is expected to reach $100 billion by 2027, driven by technological advancements and increasing demand for personalized medicine. This would allow them to capture a larger share of the diagnostics market.
- Strategic Partnerships with Healthcare Providers: Forming strategic alliances with hospitals, clinics, and laboratories can enhance Virax Biolabs' distribution network and market reach. By offering bundled solutions and integrated services, the company can become a preferred supplier for healthcare providers. These partnerships can also facilitate the adoption of Virax Biolabs' products and services, leading to increased sales and customer loyalty. The healthcare provider market is valued at $3 trillion globally, presenting a significant opportunity for collaboration and growth.
- Enhancement of Online Platform and Direct-to-Consumer Sales: Improving the functionality and user experience of its online platform can drive direct-to-consumer sales and increase brand awareness. By offering personalized recommendations, subscription services, and educational content, Virax Biolabs can attract and retain a larger customer base. The e-commerce market for healthcare products is growing rapidly, with a projected value of $500 billion by 2025. This would allow them to tap into the growing trend of online healthcare shopping.
- Diversification of Product Portfolio: Expanding the product portfolio to include a wider range of diagnostic tests and preventative healthcare solutions can reduce the company's reliance on specific products and markets. By offering tests for various infectious diseases and chronic conditions, Virax Biolabs can cater to a broader customer base and increase its revenue potential. The global market for diagnostic testing is highly diversified, with opportunities in areas such as oncology, cardiology, and autoimmune diseases. This would allow them to capitalize on emerging trends in healthcare and diagnostics.
What Threats Does VRAX Face?
- Intense competition from established biotechnology companies.
- Regulatory hurdles and compliance requirements.
- Rapid technological advancements and product obsolescence.
- Economic downturns and reduced healthcare spending.
What Are VRAX's Competitive Advantages?
- Brand recognition through ViraxClear and ViraxCare brands.
- Established distribution network across multiple international markets.
- Online platform for direct-to-consumer sales.
- Diverse product portfolio in diagnostics and preventative healthcare.
What Does VRAX Do?
Virax Biolabs Group Limited, established in 2021 and headquartered in London, specializes in the development, distribution, and marketing of diagnostic test kits, med-tech, and PPE products aimed at the prevention, detection, diagnosis, and risk management of viral diseases. The company's product portfolio includes rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests, all marketed under the ViraxClear brand. Additionally, Virax Biolabs offers med-tech and PPE products, such as employee protection equipment, infrared thermometers, pulse oximeters, masks, and gloves, under the ViraxCare brand. Beyond diagnostics and PPE, the company distributes nebulizing machines and smart wearable devices designed to help employees maintain social distancing. Virax Biolabs operates an online platform to facilitate the sale of its ViraxClear and ViraxCare products, catering to a broad spectrum of clients, including clinics, pharmacies, laboratories, hospitals, corporations, employees, individual consumers, hospital systems, and public and private institutions. The company's operational footprint spans across Europe, South America, the Asia Pacific, Sub-Saharan Africa, and other international markets. Formerly known as Virax Biolabs (Cayman) Limited, the company rebranded to Virax Biolabs Group Limited in September 2021 to reflect its expanded global focus and comprehensive service offerings in the biotechnology sector.
What Products and Services Does VRAX Offer?
- Develops and sells diagnostic test kits for viral diseases.
- Distributes rapid antibody IgC/IgM tests under the ViraxClear brand.
- Offers antigen tests, PCR tests, and neutralizing antibody tests.
- Provides med-tech and PPE products under the ViraxCare brand.
- Distributes employee protection equipment, infrared thermometers, and pulse oximeters.
- Sells masks, gloves, and other PPE products.
- Operates an online platform for direct sales of ViraxClear and ViraxCare products.
- Provides nebulizing machines and smart wearable devices for social distancing.
How Does VRAX Make Money?
- Sales of diagnostic test kits to clinics, pharmacies, and laboratories.
- Distribution of med-tech and PPE products to hospitals and corporations.
- Direct-to-consumer sales through an online platform.
- Revenue generation through international sales in Europe, South America, Asia Pacific, and Africa.
What Industry Does VRAX Operate In?
Virax Biolabs Group Limited operates within the biotechnology industry, which is characterized by rapid innovation and evolving regulatory landscapes. The market for diagnostic testing and PPE has seen significant growth due to recent global health crises, driving demand for companies offering solutions in viral disease management. The competitive landscape includes established players and emerging companies, all vying for market share. Virax Biolabs differentiates itself through its ViraxClear and ViraxCare brands, targeting a broad customer base across multiple geographic regions. The biotechnology industry is expected to continue growing, driven by advancements in diagnostic technologies and increased healthcare spending.
Who Are VRAX's Key Customers?
- Clinics and pharmacies
- Laboratories and hospitals
- Corporations and employees
- Individual consumers
- Public and private institutions
How Virax Biolabs Group Limited Is Valued
Relative to its peer group, VRAX's quantitative score of 44/100 is below the peer average of 77/100.
Company Profile
Virax Biolabs Group Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lanarkshire, GB. The company is led by CEO James Foster. VRAX has traded publicly since 2022.
Key Financial Metrics
Return on assets is -88.4%, showing how much profit it generates from its asset base. A current ratio of 9.97 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Virax Biolabs Group Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.58 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Virax Biolabs Group Limited revenue of about $40K for fiscal 2026, with EPS near $-10.00.
VRAX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Virax's upcoming product pipeline, indicating potential positive developments.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to addressing viral infections.
- Analysts have noted an increase in interest surrounding Virax's partnerships, which could enhance its market reach and credibility.
- The overall market perception of biotech firms focusing on viral solutions is improving, potentially benefiting Virax as it aligns with current health trends.
Bear Case
- Some investors remain skeptical about the scalability of Virax's solutions, fearing they may not penetrate the market as expected.
- Recent social sentiment shows a divide, with significant bearish views emerging from concerns over regulatory hurdles facing biotech companies.
- The volatility in the biotech sector has led to apprehension, with some traders expressing doubts about Virax's long-term sustainability amid fierce competition.
- Market developments indicate that larger players are also focusing on similar viral solutions, raising concerns about Virax's ability to stand out.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VRAX Latest News
-
BC-Most Active Stocks
Associated Press · Aug 19, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jul 16, 2026
-
Dow Gains 50 Points; Simulations Plus Earnings Top Views
benzinga · Jul 10, 2026
-
US Stocks Edge Higher; Delta Air Lines Posts Upbeat Q2 Earnings
benzinga · Jul 10, 2026
VRAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRAX.
Price Targets
Wall Street price target analysis for VRAX.
VRAX MoonshotScore
What does this score mean?
The MoonshotScore rates VRAX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Leadership: James Foster
Managing Director
James Foster serves as the Managing Director of Virax Biolabs Group Limited, overseeing the company's strategic direction and operational activities. His background includes experience in managing small teams and navigating the complexities of the biotechnology sector. He is responsible for driving the company's growth initiatives and ensuring the effective execution of its business plan. His leadership is crucial for steering the company through its current challenges and capitalizing on future opportunities.
Track Record: Under James Foster's leadership, Virax Biolabs Group Limited has focused on expanding its product offerings and strengthening its international presence. Key milestones include the launch of the ViraxCare brand and the development of the company's online platform. His focus is on improving operational efficiency and driving revenue growth, though the company's financial performance remains a challenge.
Virax Biolabs Group Limited Healthcare Stock: Key Questions Answered
What does the AI Score mean for VRAX?
VRAX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Virax Biolabs Group Limited focuses on diagnostics and prevention solutions for viral diseases. The company develops, sells, and distributes diagnostic test kits, med-tech, and PPE products across …
What does Virax Biolabs Group Limited do?
Virax Biolabs Group Limited is a biotechnology company that develops, distributes, and markets diagnostic test kits, med-tech, and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases. The company operates under the ViraxClear and ViraxCare brands, offering a range of products including rapid antibody tests, antigen tests, PCR tests, and PPE.
What are the main risks for VRAX?
The main risks for Virax Biolabs Group Limited include intense competition from established biotechnology companies, regulatory hurdles and compliance requirements in international markets, and the company's negative profit margin and gross margin. The company's dependence on specific products and markets also increases its vulnerability to market shifts.
What are the key factors to evaluate for VRAX?
Virax Biolabs Group Limited (VRAX) holds an AI score of 44/100 (low). Virax Biolabs Group Limited operates in the growing market for infectious disease diagnostics and prevention. Not financial advice.
How frequently does VRAX data refresh on this page?
VRAX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VRAX's recent stock price performance?
Virax Biolabs Group Limited (VRAX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in diagnostics and preventative healthcare. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRAX overvalued or undervalued right now?
Virax Biolabs Group Limited (VRAX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VRAX before investing?
Before investing in Virax Biolabs Group Limited (VRAX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VRAX to a portfolio?
Key strength of Virax Biolabs Group Limited (VRAX): Diverse product portfolio in diagnostics and preventative healthcare. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully representative of the company's current performance.
- AI analysis is pending, and analyst consensus is not available.
- The biotechnology industry is subject to rapid changes and regulatory uncertainties.